logo
  • About us
    • Reig Jofre in brief
    • Strategic pillars
    • Company history
    • Locations
  • Products
    • Product categories
    • Pharmaceutical Technologies
      • Antibiotics
      • Injectable products
      • Others
    • Specialty Products
      • Dermatology
      • Osteoarticular
      • Women’s Health
      • Pediatrics
    • Consumer healthcare
    • Healthcare professionals
      and consumers corner
  • R&D
    • R&D
    • Innovation in Collaboration
    • Pipeline
    • Joint projects
  • Services
    • CDMO services
    • CMO services
  • Investors
    • Information note
    • General information
    • Inside information
    • Other relevant information
    • Former relevant facts
    • Financial information
    • Corporate governance
    • General shareholders’ meetings
    • The share
    • Analysts covering the stock
    • Presentations
    • Webcasts
  • News
    • News and repository
    • Reig Jofre in the media (ES)
    • Subscription center
  • Social Responsibility
  • Contact
    • Contact form
    • Work with us
    • Subscription center
  • |
  • ES
  • EN

News

Transparency withour stakeholders

  • Show all
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

17 August 2020

Transactions within the share buy-back program

10 August 2020

Transactions within the share buy-back program

5 August 2020

Transactions within the share buy-back program

27 July 2020

Transactions within the share buy-back program

23 July 2020

Reig Jofre presents the second quarter 2020 results

23 July 2020

Reig Jofre releases first half 2020 results note

23 July 2020

Resolutions of the General Shareholders’ Meeting

21 July 2020

Transactions within the share buy-back program

16 July 2020

Reig Jofre contributes its know-how in the development of biological vaccines to the innovative consortium of Vaxdyn

2 July 2020

Start of the first temporary share buyback program

1 July 2020

Termination of the liquidity contract

18 June 2020

Reschedule of 1H 2020 results

17 June 2020

Reig Jofre convenes its 2020 General Shareholders´ Meeting

7 May 2020

Reig Jofre closes the first quarter of 2020 with a growth of 26% in sales

6 May 2020

Reig Jofre begins a clinical study to reduce the incidence of COVID-19 and its severity in the event of infection

23 March 2020

General Shareholders’ Meeting postponed

10 March 2020

Reig Jofre launches a new hospital medicine in Spain and Europe for the treatment of narcolepsy

28 February 2020

Reig Jofre reaches € 200 million in revenue and closes 2019 with a growth of 11% in sales and 20% in EBITDA

5 February 2020

The use of chondroprotectors (SYSADOA) would enable the NHS to avoid around 20,000 adverse effects per year, with an economic saving of more than 40 million Euros over three years

27 January 2020

Reig Jofre reaches a new milestone: 5 million vials of injectable Remifentanil marketed in Japan

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 17

Legal advice – Online store access for employees – RJF connected

© 2020 Laboratorio Reig Jofre

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Privacy Preference Center

Privacy Preferences